NSC232003 is a highly potent and cell-permeable UHRF1 inhibitor, which inhibits DNA methylation in vitro and disrupts DNMT1/UHRF1 interactions at a cellular level.
HLI 373 is an inhibitor of Hdm2 ubiquitin ligase (E3) which blocks Hdm2-mediated ubiquitylation, proteasomal degradation of p53 and activates p53-dependent transcription.
NMS-859 is a potent, covalent VCP (p97) inhibitor, with IC50s of 0.37 and 0.36 μM for wild-type VCP in the presence of 60 μM and 1 mM ATP in cells, respectively.
RA-9 is a potent and selective proteasome-associated deubiquitinating enzymes (DUBs) inhibitor with favorable toxicity profile and anticancer activity.
CC0651 is an allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme. CC0651 potently (IC50=1.72 μM) inhibits the ubiquitination of p27Kip1, as confirmed by dose-response analysis.
WS-383 is a potent, selective and reversible inhibitor of DCN1-UBC12 interaction, with an IC50 of 11 nM. WS-383 inhibits Cul3/1 neddylation, induces accumulation of p21, p27 and NRF2.
TCID (4,5,6,7-Tetrachloroindan-1,3-dione) is a potent and selective inhibitor of neuronal ubiquitin C-terminal hydrolase UCH-L3, with an IC50 of 0.6 μM. It reduces ubiquitination of the glycine transporter GlyT2 in primary neurons from the brainstem and spinal cord, making it a valuable tool for studying neuronal ubiquitin regulation and glycinergic neurotransmission.
DUB-IN-7 is a potent deubiquitinating enzyme (DUB) inhibitor. This compound selectively targets DUBs, facilitating the investigation of their role in various biological processes. DUB-IN-7 is particularly relevant for research into diseases associated with dysregulated JAK2 activity, including leukemia.
